Biomedical subjects

Da Wang

Publications and source records attributed to Da Wang.

3 recordsLinked to original sources

PubMed2026

Direct Modeling of the Interfacial Resistance in All-Solid-State Battery.

Interfacial reconstruction and its associated high resistance govern the performance of all-solid-state batteries (ASSBs). However, indirectly inferring interfacial potentials from bulk band alignments masks the true solid-solid electrochemistry, causing orders-of-magnitude discrepancies in predicting space-charge layer (SCL) resistances and impeding interface screening. Herein, by traversing 310 distinct interfaces from ∼29,000 literatures, we develop a non-empirical numerical procedure that directly maps lithium‑ion redistribution to interfacial resistance by integrating ligand‑field theory with the SCL model. Considering electric potential differences and intrinsic carrier properties during interfacial reconstruction via a modified ligand-field splitting strength (MLFSS) descriptor yields unprecedented bridging between modeling and measurement, reducing predicted resistance discrepancies from over ten orders of magnitude to within two. On this basis, we resolve the highly system-dependent controversy over oxide interfacial resistances by identifying extreme MLFSS disparities (>3.5 eV) as the decisive factor, while emphasizing ion‑intercalation sulfides (<0.2 eV) as cathodes for their intrinsic SCL suppression. The predictive capability of this tunable criterion is validated in an all-sulfide V0.5Cr1.5S4/Li10GeP2S12/75% Li2S-24% P2S5-1% P2O5/Li prototype. The resulting ultralow interfacial resistance of 8.8 Ω cm2 ensures superior cycling stability at an active-material energy density of 562 Wh kg-1, establishing a practical paradigm for breaking the energy and kinetics trade-off in ASSBs.

all‐solid‐state battery↗

PubMed2026

The Impact of Hemoglobin Concentration on Prognosis in Patients With Diabetic Foot: A Systematic Review and Meta-Analysis of Risk Factors for Adverse Outcomes and Clinical Management.

BackgroundDiabetic foot (DF) complications, including diabetic foot ulcers (DFUs), lead to significant morbidity, disability, and economic burden. Hemoglobin (Hb) levels may influence the prognosis of DF patients, but their relationship with adverse clinical outcomes remains unclear. This systematic review and meta-analysis aimed to assess the association between hemoglobin concentration and the risk of adverse outcomes in diabetic foot patients, including amputation and mortality.MethodsWe followed PRISMA guidelines to conduct a systematic literature review. A meta-analysis was performed on observational studies assessing the impact of hemoglobin levels on amputation, mortality, and ulcer incidence. A random-effects model was applied, and risk bias was evaluated using the Newcastle-Ottawa Scale.ResultsA total of 22 observational studies involving 10,984 patients were included. Our meta-analysis revealed that lower hemoglobin levels were significantly associated with a higher risk of amputation (OR = 0.97, 95% CI: 0.94-0.99, P < .001), and lower hemoglobin concentrations were found in amputation cases compared to non-amputation cases (SMD = -0.14, 95% CI: -0.24 to -0.04, P < .01). However, no significant association was found between hemoglobin levels and mortality (OR = 0.99, 95% CI: 0.33-2.89, P > .05). Sensitivity and publication bias analyses indicated robust results.ConclusionLower hemoglobin levels were associated with higher odds of amputation in patients with diabetic foot. However, pooled effects were small and heterogeneity was substantial across studies; therefore, hemoglobin likely functions primarily as a marker of overall disease burden and perioperative risk rather than a proven modifiable target. Prospective interventional studies are needed to determine whether correcting anemia improves limb outcomes and survival.

Humans↗

PubMed2026

Identification of Drug-resistant Cell Subpopulations in Colorectal Cancer Through Single-cell Analysis and Exploration of Potential Therapeutic Strategies.

INTRODUCTION: The therapeutic efficacy of Colorectal Cancer (CRC) is often compromised by resistance to the standard chemotherapy agent oxaliplatin. METHODS: This study obtained single-cell RNA sequencing (scRNA-seq) data from the Gene Expression Omnibus (GEO) database. Differentially Expressed Genes (DEGs) between resistant and sensitive epithelial subpopulations were identified, followed by enrichment analysis. Pseudotemporal trajectory and cell-cell communication were analyzed using Monocle2 and CellChat, respectively. The candidate drug was predicted by Connectivity Map (cMAP) analysis. External validation included assessment of the EpC2 signature in an oxaliplatin-resistant cell line dataset (GSE76092), survival analysis using The Cancer Genome Atlas (TCGA) cohorts, and re-analysis of the GSE179784 dataset to assess the reproducibility of EpC2-like subpopulations and their DNA Damage Repair (DDR) scores. RESULTS: Cell subpopulations were divided into 10 clusters. Among them, epithelial cells comprised 5 subpopulations, with EPC2 identified as a potential oxaliplatin-resistant subset. DEGs were enriched in the TNF and IL-17 pathways. External validation confirmed the enrichment of EpC2 in resistant cell lines and its association with poor survival. Pseudotemporal trajectory revealed that epithelial cells underwent state transitions, forming two distinct branches. The resistant group exhibited enrichment in RNA splicing and NF-κB pathways. Cell-cell communication analysis revealed interactions involving MDK- NCL and PPIA-BSG. Dasatinib was predicted as a candidate drug. DISCUSSION: We identified an oxaliplatin-resistant subpopulation of Epithelial Cells (EpC2) in CRC, elucidated its multi-layered resistance mechanisms, and integrated multi- omics and cMAP database analyses to predict a potential intervention drug. CONCLUSION: This study provided potential therapeutic possibilities for oxaliplatin resistance, contributing to CRC treatment.

Humans↗